SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TOSHI

TOSHI is currently trending as its dedicated community remains highly engaged, actively accumulating the asset and expressing strong conviction despite broader market volatility. Chatter is focused on its role as the "Face of Base" and anticipation of future catalysts like potential Tier 1 exchange listings and the upcoming Toshi Mobile launch, reinforcing its long-term utility beyond a meme coin.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN CRYPTO is trending with strong community enthusiasm following the launch of its "AirLock" feature, enabling holders to lock tokens for rewards and achieve community-owned supply control. This initiative is driving significant bullish sentiment, as participants believe it fosters a long-term HODLing culture and represents a revolutionary approach for projects on the Solana blockchain.

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Protagonist Therapeutics Inc

Protagonist Therapeutics is trending due to significant market chatter surrounding a potential acquisition by Johnson & Johnson, complementing its strong clinical pipeline. The community is highly engaged in discussions about J&J's strategic interest in PTGX's promising immunology and hematology assets, particularly the "practice-changing" rusfertide data and the efficacy of its oral IL-23 receptor antagonist, JNJ-2113.

Colliers International Group, Inc. engages in the provision of commercial real estate services to corporate and institutional clients. It offers outsourcing and advisory services, lease brokerage, and sales brokerage. It operates through the following segments: Real Estate Services, Engineering, Investment Management, and Corporate. The Real Estate Services segment relates to Americas, EMEA, and Asia Pacific regions. The Engineering segment refers to engineering and project management. The Investment Management segment is involved in a global alternative asset manager with long-standing, cycle tested expertise. The Corporate segment includes the costs of global administrative functions and corporate head office. The company was founded on July 31, 1988, and is headquartered in Toronto, Canada.

Colliers International Group Inc

Colliers International (CIGI) is trending due to its strategic partnership with Google Cloud, aimed at accelerating digital and AI-powered innovation within the commercial real estate sector. The community sees this as a pivotal move into AI infrastructure, positioning Colliers for market leadership in this evolving space. Ongoing analyst interest is also evident, reflecting the company's broader strategy of diversifying services through targeted acquisitions.

USDC is a fully collateralized US dollar stablecoin. USDC is the bridge between dollars and trading on cryptocurrency exchanges. The technology behind CENTRE makes it possible to exchange value between people, businesses and financial institutions just like email between mail services and texts between SMS providers. We believe by removing artificial economic borders, we can create a more inclusive global economy.

USD Coin

USDC is trending as a new regulatory framework for stablecoins gains traction, fostering confidence and enabling broader institutional integration. The community is actively discussing its expanding role in payments, cross-chain liquidity, and real-world asset tokenization, solidifying its position within the evolving digital finance landscape.

ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. Its products include first defense for scours, California mastitis test kits, and purified nisin intramammary treatment for mastitis. The company was founded in 1982 and is headquartered in Portland, ME.

Immucell Corp.

Immucell Corp. is drawing attention amid ongoing developments for its Re-Tain product, particularly after receiving an FDA "Incomplete Letter" that has introduced volatility. Despite this regulatory hurdle, the community is actively discussing the company's strong underlying business, evidenced by improved margins and robust performance from its First Defense line, alongside notable insider buying.

Listed Funds Trust - Teucrium 2x Long Daily XRP ETF

The Teucrium 2x Long Daily XRP ETF

The Teucrium 2x Long Daily XRP ETF (XXRP) is highly active as investors eagerly anticipate upcoming XRP spot ETF launches, particularly from Canary Capital and 21Shares, along with the recent passage of the "Genius Act" in the House. Despite widespread discussion about the leveraged ETF's inherent volatility and decay, the community is actively buying significant dips, seeing them as opportunities for massive gains as they bet on XRP's broader adoption and a potential market surge.

Roundhill ETF Trust - Roundhill Ether Covered Call Strategy ETF

oundhill Ether Covered Call Strategy ETF

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Quoin Pharmaceuticals Ltd - ADR

Quoin Pharmaceuticals is trending after announcing the successful achievement of target rapamycin loadings for two proprietary topical delivery technologies, advancing its rare disease pipeline. This news, coupled with its extremely low float and recent significant private placement funding, is driving intense community speculation about a potential short squeeze. Traders are actively debating its volatile price action and the possibility of substantial upside, comparing its potential to other low-float runners.

Inflection Point Acquisition Corp. IV is a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Andrew Stephen Gundlach and Michel Combes on June 24, 2024 and is headquartered in New York, NY.

Inflection Point Acquisition Corp. IV - Ordinary Shares - Class A

Bleichroeder Acquisition Corp I

Bleichroeder Acquisition Corp I (BACQ) is trending after repeated bullish mentions from Citron Research, highlighting its anticipated merger with Merlin Labs, a defense technology company focused on AI-enabled autonomous flight. The community is actively discussing Merlin's significant government contracts and partnerships with major aerospace firms, seeing it as a compelling, undervalued opportunity in the national security and AI sectors with limited downside near its NAV.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$GLUE @ClinicalTrialsDaily Nice posts. I would like to know if these posts / opinions  are your ideas or A.I.&#39;s ?

$GLUE 4/4 responders in the target population is exactly what you want to see. Dropping the dead weight (breast cancer arm) makes this a pure-play prostate cancer story now. ASCO GU in Feb is the next big catalyst. Loading zone. 🚀  
 
See analysis https://www.clinicaltrialsdaily.com/monterosa-prostate-cancer/

With a 100% response rate (small sample size) in AR-mutant patients, MRT-2359 validates the GSPT1 degradation thesis, signaling a major disruption for the post-taxane mCRPC landscape. * These analyses reflect my personal opinions and may include input from multiple sources.

Monte Rosa's Molecular Glue Cracks the Resistance Code in Advanced Prostate Cancer

StockTwits Web

Monte Rosa Therapeutics Inc

Jitesh Rana, MD

 Nice posts. I would like to know if these posts / opinions  are your ideas or A.I.'s ?

LabPsycho

@LabPsycho I use both AI and human help. The process starts with collating epidemiological information on an indication. Looking for untreated population and market opportunity; competitors in the area; stage of development endpoints used, efficacy and safety data. pricing information available. Market sentiment; search for any verbatim we can find from KOLs and patients. Finally synthesizing text with AI help and human curation.

StockTwits for iOS

 I use both AI and human help. The process starts with collating epidemiological information on an indication. Looking for untreated population and market opportunity; competitors in the area; stage of development endpoints used, efficacy and safety data. pricing information available. Market sentiment; search for any verbatim we can find from KOLs and patients. Finally synthesizing text with AI help and human curation.

@ClinicalTrialsDaily Great. That is what I was thinking...you had some human ideas + A.I. Refinement. Good post on GLUE.

 Great. That is what I was thinking...you had some human ideas + A.I. Refinement. Good post on GLUE.

@LabPsycho honestly all started with me looking for investments ideas for myself and it grew from there. I have been looking primarily at small caps that may be acquisition targets. I look for strategic fits, cash runway, potential opportunities to raise capital; value of new data.

 honestly all started with me looking for investments ideas for myself and it grew from there. I have been looking primarily at small caps that may be acquisition targets. I look for strategic fits, cash runway, potential opportunities to raise capital; value of new data.